Australia: Incannex Healthcare looks to US for US$27m IPO

The Australian developer of synthetic cannabidiol and psychedelic medicine therapies, Incannex Healthcare, has filed a registration statement with the Securities Exchange Commission (SEC) for the a proposed IPO of ADS which will represent 50 shares of Incannex. Pricing of the shares for the IPO, which will raise US$27m, is yet to be announced but will…

You must be a HMI Subscriber to view this content.

Subscribe Now »